POTASSIUM ION CHANNEL MODULATORS & USES THEREOF

Compounds of formula (I) and pharmacologically acceptable salts and pro- drugs wherein: Ar1 and Ar 2 =aryl orheteroaryl; a = 0 to 5; R1 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SUTHAHARAN, KANESALINGAM, LAWTON, GEOFF, KHAN, NAWAZ, MOHAMMED, EDWARDS, SIMON, DAVID, KIMBERLY, MERIEL, RUTH
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SUTHAHARAN, KANESALINGAM
LAWTON, GEOFF
KHAN, NAWAZ, MOHAMMED
EDWARDS, SIMON, DAVID
KIMBERLY, MERIEL, RUTH
description Compounds of formula (I) and pharmacologically acceptable salts and pro- drugs wherein: Ar1 and Ar 2 =aryl orheteroaryl; a = 0 to 5; R1 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano and, where a is >1, each R1 is thesame or different; b =0 to 5; R2 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano andwhere b is >1, each R2 is the same or different; V =(CR3a R3b )p SO 2 N(R3b )X and (CR3a R3b ) pN(R3b )SO2 (X); W =NR4a, O, S, S=O, SO2 and C(R4a R 4b )2; X =hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aryloxyalkyl, polyalkylene glycol residues, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl and alkyl groups substituted with >1 NR8R9 groups wherein R8 and R9 +nitrogen atom form a saturated or partially unsaturated heterocyclic group which isoptionally further substituted by >1 substituents selected from alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, nitro, amino, monoalkylamino, dialkylamino and hydroxyl; Y and Z each =(CR 5a R 5b ) n1, C=O, SO2, C(=O)NR 5a, C(=O)NR5a SO2 or C=O(R5a R 5b) n2; R3a, R3b, R4a, R4b, R5a and R5b each =hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; n1 and n2 each =0 to 2; and p =0 to 2; are excellent selective modulators of potassium ion flux through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treating and preventing a number of conditions including pain and lower urinary tract disorders. L'invention porte sur des composés représentés par la formule (I) et sur des sels pharmacologiquement acceptables et des promédicaments de ceux-ci. Dans cette formule : Ar1 et Ar2= aryle ou hétéroaryle ; a = 0 à 5 ; R1 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et, si a est > 1, les R1 sont identiques ou différents ; b = 0 à 5 ; R2 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et si b est > 1, les R2 sont identiques ou différents ; V = (CR3a R3b)pSO2N(R3b)X et (CR3a R3b)pN(R3b)SO2(X) ; W = NR4a, O, S, S=O, SO2 et C(R4aR4b)2; X
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2009071947A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2009071947A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2009071947A23</originalsourceid><addsrcrecordid>eNrjZNAP8A9xDA72DPVV8PT3U3D2cPTzc_VR8PV3CfVxDPEPClZQUwgNdg1WCPFwDXL1d-NhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGBpYG5oaWJuaORsbEqQIAoj0m9w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>POTASSIUM ION CHANNEL MODULATORS &amp; USES THEREOF</title><source>esp@cenet</source><creator>SUTHAHARAN, KANESALINGAM ; LAWTON, GEOFF ; KHAN, NAWAZ, MOHAMMED ; EDWARDS, SIMON, DAVID ; KIMBERLY, MERIEL, RUTH</creator><creatorcontrib>SUTHAHARAN, KANESALINGAM ; LAWTON, GEOFF ; KHAN, NAWAZ, MOHAMMED ; EDWARDS, SIMON, DAVID ; KIMBERLY, MERIEL, RUTH</creatorcontrib><description>Compounds of formula (I) and pharmacologically acceptable salts and pro- drugs wherein: Ar1 and Ar 2 =aryl orheteroaryl; a = 0 to 5; R1 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano and, where a is &gt;1, each R1 is thesame or different; b =0 to 5; R2 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano andwhere b is &gt;1, each R2 is the same or different; V =(CR3a R3b )p SO 2 N(R3b )X and (CR3a R3b ) pN(R3b )SO2 (X); W =NR4a, O, S, S=O, SO2 and C(R4a R 4b )2; X =hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aryloxyalkyl, polyalkylene glycol residues, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl and alkyl groups substituted with &gt;1 NR8R9 groups wherein R8 and R9 +nitrogen atom form a saturated or partially unsaturated heterocyclic group which isoptionally further substituted by &gt;1 substituents selected from alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, nitro, amino, monoalkylamino, dialkylamino and hydroxyl; Y and Z each =(CR 5a R 5b ) n1, C=O, SO2, C(=O)NR 5a, C(=O)NR5a SO2 or C=O(R5a R 5b) n2; R3a, R3b, R4a, R4b, R5a and R5b each =hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; n1 and n2 each =0 to 2; and p =0 to 2; are excellent selective modulators of potassium ion flux through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treating and preventing a number of conditions including pain and lower urinary tract disorders. L'invention porte sur des composés représentés par la formule (I) et sur des sels pharmacologiquement acceptables et des promédicaments de ceux-ci. Dans cette formule : Ar1 et Ar2= aryle ou hétéroaryle ; a = 0 à 5 ; R1 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et, si a est &gt; 1, les R1 sont identiques ou différents ; b = 0 à 5 ; R2 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et si b est &gt; 1, les R2 sont identiques ou différents ; V = (CR3a R3b)pSO2N(R3b)X et (CR3a R3b)pN(R3b)SO2(X) ; W = NR4a, O, S, S=O, SO2 et C(R4aR4b)2; X = hydroxyalkyle, alcoxyalkyle, haloalcoxyalkyle, aryloxyalkyle, restes de polyalkylène glycol, groupes aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle et alkyle substitués par plus d'un groupe NR8R9, où R8 et R9 + atome d'azote forment un groupe hétérocyclique saturé ou partiellement insaturé qui est facultativement encore substitué par plus d'un substituant choisi parmi alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, nitro, amino, monoalkylamino, dialkylamino et hydroxyle ; Y et Z représentent chacun (CR5aR5b)n1, C=O, SO2, C(=O)NR5a, C(=O)NR5aSO2 ou C=O(R5aR5b)n2 ; R3a, R3b, R4a, R4b, R5a et R5b représentent chacun hydrogène, alkyle, cycloalkyle, aryle ou hétéroaryle ; n1 et n2 représentent chacun 0 à 2 ; et p = 0 à 2. Ces composés et leurs sels promédicaments sont d'excellents modulateurs sélectifs du flux d'ions potassium à travers les canaux KCNQ2, KCNQ3 et/ou KCNQ2/3, les rendant aptes à être utilisés dans le traitement et la prévention d'un nombre d'états comprenant la douleur et les troubles du tractus urinaire inférieur.</description><language>eng ; fre</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20090611&amp;DB=EPODOC&amp;CC=WO&amp;NR=2009071947A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20090611&amp;DB=EPODOC&amp;CC=WO&amp;NR=2009071947A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SUTHAHARAN, KANESALINGAM</creatorcontrib><creatorcontrib>LAWTON, GEOFF</creatorcontrib><creatorcontrib>KHAN, NAWAZ, MOHAMMED</creatorcontrib><creatorcontrib>EDWARDS, SIMON, DAVID</creatorcontrib><creatorcontrib>KIMBERLY, MERIEL, RUTH</creatorcontrib><title>POTASSIUM ION CHANNEL MODULATORS &amp; USES THEREOF</title><description>Compounds of formula (I) and pharmacologically acceptable salts and pro- drugs wherein: Ar1 and Ar 2 =aryl orheteroaryl; a = 0 to 5; R1 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano and, where a is &gt;1, each R1 is thesame or different; b =0 to 5; R2 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano andwhere b is &gt;1, each R2 is the same or different; V =(CR3a R3b )p SO 2 N(R3b )X and (CR3a R3b ) pN(R3b )SO2 (X); W =NR4a, O, S, S=O, SO2 and C(R4a R 4b )2; X =hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aryloxyalkyl, polyalkylene glycol residues, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl and alkyl groups substituted with &gt;1 NR8R9 groups wherein R8 and R9 +nitrogen atom form a saturated or partially unsaturated heterocyclic group which isoptionally further substituted by &gt;1 substituents selected from alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, nitro, amino, monoalkylamino, dialkylamino and hydroxyl; Y and Z each =(CR 5a R 5b ) n1, C=O, SO2, C(=O)NR 5a, C(=O)NR5a SO2 or C=O(R5a R 5b) n2; R3a, R3b, R4a, R4b, R5a and R5b each =hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; n1 and n2 each =0 to 2; and p =0 to 2; are excellent selective modulators of potassium ion flux through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treating and preventing a number of conditions including pain and lower urinary tract disorders. L'invention porte sur des composés représentés par la formule (I) et sur des sels pharmacologiquement acceptables et des promédicaments de ceux-ci. Dans cette formule : Ar1 et Ar2= aryle ou hétéroaryle ; a = 0 à 5 ; R1 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et, si a est &gt; 1, les R1 sont identiques ou différents ; b = 0 à 5 ; R2 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et si b est &gt; 1, les R2 sont identiques ou différents ; V = (CR3a R3b)pSO2N(R3b)X et (CR3a R3b)pN(R3b)SO2(X) ; W = NR4a, O, S, S=O, SO2 et C(R4aR4b)2; X = hydroxyalkyle, alcoxyalkyle, haloalcoxyalkyle, aryloxyalkyle, restes de polyalkylène glycol, groupes aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle et alkyle substitués par plus d'un groupe NR8R9, où R8 et R9 + atome d'azote forment un groupe hétérocyclique saturé ou partiellement insaturé qui est facultativement encore substitué par plus d'un substituant choisi parmi alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, nitro, amino, monoalkylamino, dialkylamino et hydroxyle ; Y et Z représentent chacun (CR5aR5b)n1, C=O, SO2, C(=O)NR5a, C(=O)NR5aSO2 ou C=O(R5aR5b)n2 ; R3a, R3b, R4a, R4b, R5a et R5b représentent chacun hydrogène, alkyle, cycloalkyle, aryle ou hétéroaryle ; n1 et n2 représentent chacun 0 à 2 ; et p = 0 à 2. Ces composés et leurs sels promédicaments sont d'excellents modulateurs sélectifs du flux d'ions potassium à travers les canaux KCNQ2, KCNQ3 et/ou KCNQ2/3, les rendant aptes à être utilisés dans le traitement et la prévention d'un nombre d'états comprenant la douleur et les troubles du tractus urinaire inférieur.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNAP8A9xDA72DPVV8PT3U3D2cPTzc_VR8PV3CfVxDPEPClZQUwgNdg1WCPFwDXL1d-NhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGBpYG5oaWJuaORsbEqQIAoj0m9w</recordid><startdate>20090611</startdate><enddate>20090611</enddate><creator>SUTHAHARAN, KANESALINGAM</creator><creator>LAWTON, GEOFF</creator><creator>KHAN, NAWAZ, MOHAMMED</creator><creator>EDWARDS, SIMON, DAVID</creator><creator>KIMBERLY, MERIEL, RUTH</creator><scope>EVB</scope></search><sort><creationdate>20090611</creationdate><title>POTASSIUM ION CHANNEL MODULATORS &amp; USES THEREOF</title><author>SUTHAHARAN, KANESALINGAM ; LAWTON, GEOFF ; KHAN, NAWAZ, MOHAMMED ; EDWARDS, SIMON, DAVID ; KIMBERLY, MERIEL, RUTH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2009071947A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2009</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SUTHAHARAN, KANESALINGAM</creatorcontrib><creatorcontrib>LAWTON, GEOFF</creatorcontrib><creatorcontrib>KHAN, NAWAZ, MOHAMMED</creatorcontrib><creatorcontrib>EDWARDS, SIMON, DAVID</creatorcontrib><creatorcontrib>KIMBERLY, MERIEL, RUTH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SUTHAHARAN, KANESALINGAM</au><au>LAWTON, GEOFF</au><au>KHAN, NAWAZ, MOHAMMED</au><au>EDWARDS, SIMON, DAVID</au><au>KIMBERLY, MERIEL, RUTH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>POTASSIUM ION CHANNEL MODULATORS &amp; USES THEREOF</title><date>2009-06-11</date><risdate>2009</risdate><abstract>Compounds of formula (I) and pharmacologically acceptable salts and pro- drugs wherein: Ar1 and Ar 2 =aryl orheteroaryl; a = 0 to 5; R1 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano and, where a is &gt;1, each R1 is thesame or different; b =0 to 5; R2 =alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl, amino, monalkylamino, dialkylamino, nitro, acylamino, alkoxycarbonylamino, alkylsulphonyl, alkylsulphonylamino and cyano andwhere b is &gt;1, each R2 is the same or different; V =(CR3a R3b )p SO 2 N(R3b )X and (CR3a R3b ) pN(R3b )SO2 (X); W =NR4a, O, S, S=O, SO2 and C(R4a R 4b )2; X =hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aryloxyalkyl, polyalkylene glycol residues, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl and alkyl groups substituted with &gt;1 NR8R9 groups wherein R8 and R9 +nitrogen atom form a saturated or partially unsaturated heterocyclic group which isoptionally further substituted by &gt;1 substituents selected from alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, nitro, amino, monoalkylamino, dialkylamino and hydroxyl; Y and Z each =(CR 5a R 5b ) n1, C=O, SO2, C(=O)NR 5a, C(=O)NR5a SO2 or C=O(R5a R 5b) n2; R3a, R3b, R4a, R4b, R5a and R5b each =hydrogen, alkyl, cycloalkyl, aryl or heteroaryl; n1 and n2 each =0 to 2; and p =0 to 2; are excellent selective modulators of potassium ion flux through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treating and preventing a number of conditions including pain and lower urinary tract disorders. L'invention porte sur des composés représentés par la formule (I) et sur des sels pharmacologiquement acceptables et des promédicaments de ceux-ci. Dans cette formule : Ar1 et Ar2= aryle ou hétéroaryle ; a = 0 à 5 ; R1 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et, si a est &gt; 1, les R1 sont identiques ou différents ; b = 0 à 5 ; R2 = alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, hydroxyle, amino, monalkylamino, dialkylamino, nitro, acylamino, alcoxycarbonylamino, alkylsulfonyle, alkylsulfonylamino et cyano et si b est &gt; 1, les R2 sont identiques ou différents ; V = (CR3a R3b)pSO2N(R3b)X et (CR3a R3b)pN(R3b)SO2(X) ; W = NR4a, O, S, S=O, SO2 et C(R4aR4b)2; X = hydroxyalkyle, alcoxyalkyle, haloalcoxyalkyle, aryloxyalkyle, restes de polyalkylène glycol, groupes aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle et alkyle substitués par plus d'un groupe NR8R9, où R8 et R9 + atome d'azote forment un groupe hétérocyclique saturé ou partiellement insaturé qui est facultativement encore substitué par plus d'un substituant choisi parmi alkyle, halogène, haloalkyle, alcoxy, alcoxycarbonyle, carboxyle, nitro, amino, monoalkylamino, dialkylamino et hydroxyle ; Y et Z représentent chacun (CR5aR5b)n1, C=O, SO2, C(=O)NR5a, C(=O)NR5aSO2 ou C=O(R5aR5b)n2 ; R3a, R3b, R4a, R4b, R5a et R5b représentent chacun hydrogène, alkyle, cycloalkyle, aryle ou hétéroaryle ; n1 et n2 représentent chacun 0 à 2 ; et p = 0 à 2. Ces composés et leurs sels promédicaments sont d'excellents modulateurs sélectifs du flux d'ions potassium à travers les canaux KCNQ2, KCNQ3 et/ou KCNQ2/3, les rendant aptes à être utilisés dans le traitement et la prévention d'un nombre d'états comprenant la douleur et les troubles du tractus urinaire inférieur.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2009071947A2
source esp@cenet
subjects ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title POTASSIUM ION CHANNEL MODULATORS & USES THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A07%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SUTHAHARAN,%20KANESALINGAM&rft.date=2009-06-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2009071947A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true